Merck Reports Phase 3 extension Data for Lorlatinib in Esophageal cancer

Merck today announced Phase 3 extension results for Lorlatinib in patients with Esophageal cancer. The study demonstrated that Lorlatinib demonstrates superior efficacy vs standard of care compared to standard of care or placebo. These results provide important insights into the treatment of Esophageal cancer and support the continued development of Lorlatinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Lorlatinib was consistent with previous observations, with no new safety signals identified.